Clinical trial
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy (PDR).
NCT01281098 is registered in ClinicalTrials.gov with Association for Innovation and Biomedical Research on Light and Image as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy (PDR).
- Lead sponsor
- Association for Innovation and Biomedical Research on Light and Image
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2010
- Completion date
- February 28, 2013
- Enrollment
- 22 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diabetes mellitus type i, diabetes mellitus type ii, high risk proliferative diabetic retinopathy